OncoMatch/Clinical Trials/NCT06622005
SX-682 in Combination With Carfilzomib, Daratumumab-Hyaluronidase, and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma
Is NCT06622005 recruiting? Yes, currently enrolling (May 2026). This Phase 1 trial studies multiple treatments including Cxcr1/2 Inhibitor SX-682 and Daratumumab and Recombinant Human Hyaluronidase for recurrent multiple myeloma.
Treatment: Cxcr1/2 Inhibitor SX-682 · Daratumumab and Recombinant Human Hyaluronidase · Carfilzomib · Dexamethasone — This phase I trial tests the safety and side effects of SX-682 in combination with standard of care treatment carfilzomib, daratumumab-hyaluronidase, and dexamethasone in treating patients with multiple myeloma that has come back after a period of improvement (relapsed) or that has not responded to previous treatment (refractory). SX-682 works by blocking certain sites on cells that suppress the ability of the immune system to destroy tumor cells. Blocking those specific sites allows other cells of the immune system to become "free" to kill tumor cells. Carfilzomib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Daratumumab is in a class of medications called monoclonal antibodies. It binds to a protein called CD38, which is found on some types of immune cells and tumor cells, including myeloma cells. Daratumumab may block CD38 and help the immune system kill tumor cells, while hyaluronidase helps to deliver daratumumab to CD38-expressing tumor cells through a subcutaneous injection. Dexamethasone is in a class of medications called corticosteroids. It is known to kill myeloma cells and is also used to reduce inflammation and lower the body's immune response to monoclonal antibodies like dratumumab and help lessen its side effects. Giving SX-682 in combination with carfilzomib, daratumumab-hyaluronidase and dexamethasone may be safe and tolerable in treating patients with relapsed or refractory multiple myeloma
Check if I qualifyExtracted eligibility criteria
Cancer type
Multiple Myeloma
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Cannot have received: carfilzomib (carfilzomib)
Refractory to prior carfilzomib (i.e. relapse or progression on or within 60 days after completion of treatment)
Cannot have received: daratumumab (daratumumab)
Refractory to prior daratumumab (i.e. relapse or progression on or within 60 days after completion of treatment)
Lab requirements
Blood counts
Absolute neutrophil count: ≥ 3 x 10^9/L; Platelets: ≥ 75 x 10^9/L; Hemoglobin: ≥ 7 g/dL
Kidney function
Estimated creatinine clearance ≥ 45 mL/min (Cockroft-Gault)
Liver function
Total bilirubin: ≤ 1.5 x upper limit of normal (ULN): ≤ 3.0 x ULN for Gilbert's syndrome; AST/ALT ≤ 3 x ULN
Cardiac function
Left ventricular ejection fraction of at least 50%
Absolute neutrophil count: ≥ 3 x 10^9/L; Platelets: ≥ 75 x 10^9/L; Hemoglobin: ≥ 7 g/dL; Total bilirubin: ≤ 1.5 x upper limit of normal (ULN): ≤ 3.0 x ULN for Gilbert's syndrome; AST/ALT ≤ 3 x ULN; Estimated creatinine clearance ≥ 45 mL/min (Cockroft-Gault); Left ventricular ejection fraction of at least 50%
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Roswell Park Comprehensive Cancer Center · Buffalo, New York
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify